Ubie’s growth has been accelerated by recent strategic investment and acceptance into Mayo Clinic Platform Accelerate program

 Ubie, an AI-driven and medically vetted healthcare prediction platform that guides patients to the care they need, announced that its cumulative funding since the company’s founding in 2017 has reached over $125Million. The funding includes a recent investment and support from leading companies worldwide, including Google, JAPAN POST CAPITAL Co., Ltd., NTT DOCOMO, INC., SEVEN-ELEVEN JAPAN CO., LTD., Japan Finance Corporation, and The Shoko Chukin Bank, Ltd.

Health Technology Insights: First Patient Enrolled in Aclarion’s Groundbreaking CLARITY Trial

Ubie previously announced Series C funding of $26.2M, with a cumulative total of $59.8M in August 2022. In the US, Ubie’s highly accurate, medically-validated AI Symptom Checker has driven partnerships with key advocacy and life sciences companies. The number of users of Symptom Checker in the US recently reached over 4 million total users, with an 85% increase of monthly organic users since 2024.

Health Technology Insights: Cherokee Health Systems Rebrands as River Valley Health

“Ubie has seen an increasing understanding and acknowledgment of the capabilities and impact we provide to patients, providers, and the healthcare system,” said Kota Kubo, Co-Founder and CEO of Ubie. “Our growth has been significant and multifaceted, supported by a growing user base, new customers, partnerships with key groups, and funding from established companies in healthcare. We continue to see increasing interest in our solution in the US, where we are currently focusing expansion efforts for patients, providers and pharmaceutical partners.”

Generative AI and Provider Solutions

Ubie’s approach of helping users navigate the burdensome, and sometimes difficult to understand, healthcare system has resonated with users and partners alike, resulting in the company accelerating the reach and impact of its Symptom Checker solution. Ubie is now working to implement generative AI in a way that will further enhance patient education, providing critical disease information and guidance toward appropriate care and treatments as early as possible in their journey.

Ubie is also developing a provider solution following its acceptance into the Mayo Clinic’s Platform Accelerate program, which will allow Ubie to pressure test and fine tune the platform using the de-identified data of 3 million Mayo Clinic patients to refine the platform’s accuracy.

Ubie Worldwide

Ubie’s Symptom Checker is used by over 13 million people monthly worldwide, while in Japan Ubie offers the “Ubie Medical Navigator,” a tool for medical institutions that provides solutions such as AI-powered patient intake and generative AI, has been adopted by over 1,800 medical institutions, and “Ubie for Pharma,” which provides disease and treatment awareness information in collaboration with pharmaceutical companies.

These services support Ubie’s aim of promoting the creation of a society where everyone can access appropriate medical care. The company is focused on creating significant synergies by combining the strengths of leading companies in Japan and overseas, including their advanced technological capabilities and nationwide networks, with Ubie’s knowledge and technology in healthcare.

Health Technology Insights: LIfT BioSciences Expands U.S. Footprint with New Facility at Portal Innovations

To participate in our interviews, please write to our HealthTech Media Room at sudipto@intentamplify.com

Source – PR Newswire